SGS to expand bioanalytical testing capabilities

10 Dec 2018

The €3.5 million investment in equipment, facilities and expert staff will significantly increase the capabilities at the site to match increasing demand and shorten processes for pharmaceutical clients.

SGS is investing €3.5 million to undertake a two-phase expansion project at its laboratory in Poitiers, France, to implement a 50% increase in bioanalytical capabilities at the site by 2020.

SGS to expand bioanalytical testing capabilities

The initial phase of the project was completed in November 2018, with the delivery of a new, 150-m2 immunoassay laboratory, equipped with eight instruments (MSD, ELISA, Luminex, Ella) and with the capacity to employ 20 analysts.

The second phase of the expansion will commence with the construction of a new, 800-m2 building, housing both a new laboratory and office space, and the renovation of the existing laboratory at the site. Alongside the renovation works will be the introduction of a new electronic laboratory notebook system across the entire facility, as well as upgrades to the site's quality management system and sample automation capabilities.

Recruitment of new staff, which has seen an increase of over 25% over the past 2 years, is set to continue and will further accelerate by Q3 2019.

A4lain Renoux, Laboratory Director, said: "This major investment in equipment, facilities and expert staff will significantly increase the capabilities at the site to match increasing demand and shorten processes for our pharmaceutical clients. SGS has a commitment to offer a global presence with a center of excellence model, and it is through investment in both the state-of-the-art facilities and staff that we can meet this ambition."

Read More

Related news

Can the industry really claim it's 'business as usual'?

Can the industry really claim it's 'business as usual'?

19 May 2020

ChargePoint Technology's Chief Commercial Officer says "yes" it can.

Read more 
HKBU scientists develop technique to eliminate drug side effects

HKBU scientists develop technique to eliminate drug side effects

19 May 2020

The novel method paves the way towards the mass production of affordable therapeutic drugs that are made with recyclable materials.

Read more 
Samsung Biologics expands business continuity excellence with additional ISO 22301 certification

Samsung Biologics expands business continuity excellence with additional ISO 22301 certification

19 May 2020

The certification is expected to instill greater 'supply' trust with clients, particularly during the current pandemic.

Read more 
Vibalogics agrees to additional manufacturing for lead COVID-19 vaccine candidate of J&J unit

Vibalogics agrees to additional manufacturing for lead COVID-19 vaccine candidate of J&J unit

18 May 2020

CDMO is contracted to produce multiple clinical batches from German facility

Read more 
Pharmapack expert recommends holistic approach to sustainability

Pharmapack expert recommends holistic approach to sustainability

18 May 2020

Although the industry might be 30% along its sustainability journey, greater interoperability is needed from materials to devices.

Read more 
KND Labs earns Active Pharmaceutical Ingredients certification for CBD ingredients

KND Labs earns Active Pharmaceutical Ingredients certification for CBD ingredients

12 May 2020

Company's manufacturing methods and processes reviewed by an independent third-party auditor to ensure the products have the highest-quality ingredients possible.

Read more 
Characterizing virus and virus-like particles

Characterizing virus and virus-like particles

12 May 2020

New application study describes the separation and characterisation of adeno associated virus serotypes by AF4.

Read more 
Recipharm increases API and raw material stocks to ensure supply amid higher antibiotics demand

Recipharm increases API and raw material stocks to ensure supply amid higher antibiotics demand

12 May 2020

CDMO says it has made "notable changes" to its supply chain processes to ensure continuing supply of medicines during COVID-19 pandemic

Read more 
AI technology company launches with Novartis and Sarepta deals

AI technology company launches with Novartis and Sarepta deals

11 May 2020

Collaborations focus on gene therapies for serious eye and muscle diseases using Dyno’s CapsidMap artificial intelligence platform to design AAV vectors.

Read more 
Demand for immunity products to be sustained long-term says SIRIO

Demand for immunity products to be sustained long-term says SIRIO

11 May 2020

Movement towards healthy lifestyles and preventative supplements the lasting behavioural change post COVID-19.

Read more